HCWB

HCW Biologics Inc

HCWB, USA

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer. The company has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

https://www.hcwbiologics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
HCWB
stock
HCWB

Insiders' US$3.05m Investments In Red Following HCW Biologics' US$1.1m Dip In Market Value simplywall.st

Read more →
HCWB
stock
HCWB

HCW Biologics Secures $4M Through Warrant Exercise TipRanks

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$35

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-1.94

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

216.13 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-17.90 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-20,760.87 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 1.72% of the total shares of HCW Biologics Inc

1.

Golden State Wealth Management, LLC

(0.4648%)

since

2025/06/30

2.

UBS Group AG

(0.4424%)

since

2025/06/30

3.

Fidelity Extended Market Index

(0.2698%)

since

2025/07/31

4.

Vanguard Institutional Extnd Mkt Idx Tr

(0.1941%)

since

2025/07/31

5.

Spartan Extended Market Index Pool F

(0.0888%)

since

2025/07/31

6.

Wells Fargo & Co

(0.079%)

since

2025/06/30

7.

Fidelity Series Total Market Index

(0.044%)

since

2025/07/31

8.

Fidelity Total Market Index

(0.0337%)

since

2025/07/31

9.

Spartan Total Market Index Pool G

(0.029%)

since

2025/07/31

10.

Fidelity Nasdaq Composite Index

(0.0191%)

since

2025/07/31

11.

Tower Research Capital LLC

(0.0116%)

since

2025/06/30

12.

Northern Trust Extended Eq Market Idx

(0.0106%)

since

2025/06/30

13.

NT Ext Equity Mkt Idx Fd - L

(0.0106%)

since

2025/06/30

14.

ZWJ Balanced

(0.0037%)

since

2025/06/30

15.

State St US Extended Mkt Indx NL Cl C

(0.0035%)

since

2025/08/31

16.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.003%)

since

2025/06/30

17.

Fortitude Family Office LLC

(0.0027%)

since

2025/06/30

18.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0025%)

since

2024/12/31

19.

SSgA U.S. Total Market Index Strategy

(0.0015%)

since

2025/03/31

20.

Northern Trust Wilshire 5000

(0.0013%)

since

2025/06/30

21.

Advisor Group Holdings, Inc.

(0.0012%)

since

2025/06/30

22.

State St US Ttl Mkt Indx NL Cl A

(0.0011%)

since

2025/08/31

23.

Bank of America Corp

(0.0005%)

since

2025/06/30

24.

SBI Securities Co Ltd

(0.0003%)

since

2025/06/30

25.

Fidelity U.S. Equity Index Ins Trust

(0.0002%)

since

2025/07/31

26.

State Street Corp

(0%)

since

2025/06/30

27.

BlackRock Inc

(0%)

since

2025/06/30

28.

Northern Trust Corp

(0%)

since

2025/06/30

29.

Bridgeway Capital Management, LLC

(0%)

since

2025/03/31

30.

JustInvest LLC

(0%)

since

2025/06/30

31.

Two Sigma Investments LLC

(0%)

since

2025/03/31

32.

Virtu Financial LLC

(0%)

since

2025/03/31

33.

XTX Topco Ltd

(0%)

since

2025/03/31

34.

AE Wealth Management LLC

(0%)

since

2025/06/30

35.

J.W. COLE ADVISORS, INC.

(0%)

since

2025/06/30

36.

HighTower Advisors, LLC

(0%)

since

2025/03/31

37.

Cresset Asset Management, LLC

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-2.0151

EPS Estimate

—

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Wide Moat Company(6.3)
GARP
Fair GARP(4.5)
Growth
Moderate Growth(4.5)
Momentum
Moderate Momentum(5)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

HCW Biologics Inc (HCWB) Stock Details & Analysis - Finnton | Finnton